SPDEF drives pancreatic adenocarcinoma progression via transcriptional upregulation of S100A16 and activation of the PI3K/AKT signaling pathway
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sam
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Pancreatic adenocarcinoma (PAAD) is an aggressive cancer with poor outcomes.
- Understanding PAAD molecular drivers is crucial for new therapies.
Purpose Of The Study
- To investigate the role of Sam's pointed domain-containing ETS transcription factor (SPDEF) in PAAD progression.
- To identify SPDEF's molecular targets and signaling pathways involved in PAAD.
Main Methods
- Utilized The Cancer Genome Atlas (TCGA) database for gene expression analysis.
- Performed in vitro experiments to assess SPDEF's effects on pancreatic cancer cells.
- Analyzed SPDEF-targeted genes and downstream signaling pathways.
Main Results
- SPDEF is a core gene in PAAD and a potential prognostic marker.
- Increased SPDEF expression promotes PAAD cell proliferation, migration, and invasion while reducing apoptosis.
- SPDEF upregulates S100A16 transcription, activating the PI3K/AKT pathway.
Conclusions
- SPDEF plays a critical role in promoting PAAD progression.
- Targeting SPDEF and its downstream pathways, like PI3K/AKT, offers potential therapeutic strategies for PAAD.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...